1,227
Views
19
CrossRef citations to date
0
Altmetric
Research Article

Long-term survival with peritoneal mucinous carcinomatosis from intraductal mucinous papillary pancreatic carcinoma treated with complete cytoreduction and hyperthermic intraperitoneal chemotherapy

, , , , &
Pages 408-411 | Received 17 May 2014, Accepted 03 Aug 2014, Published online: 26 Sep 2014

Figures & data

Figure 1. Axial T2 MR imaging: mucinous ascites with several peritoneal implants. White arrow shows the mucinous ascites over the liver surface.

Figure 1. Axial T2 MR imaging: mucinous ascites with several peritoneal implants. White arrow shows the mucinous ascites over the liver surface.

Figure 2. (A) Haematoxylin and eosin-stained section from tumour tissue in the abdominal cavity: there is extensive dissection of mucous material in the adipose tissue and mucinous epithelium with little nuclear atypia (20×). (B) The mucous material is positive with PAS-diastase and (C) MUC4. The epithelium (D) is CK7 weak-irregular positive but (E) CK17 and (F) CEA strongly positive; (G) CK20 and (H) CA125 are negative. (I) p53 shows nuclear positivity in only half of the tumour cells.

Figure 2. (A) Haematoxylin and eosin-stained section from tumour tissue in the abdominal cavity: there is extensive dissection of mucous material in the adipose tissue and mucinous epithelium with little nuclear atypia (20×). (B) The mucous material is positive with PAS-diastase and (C) MUC4. The epithelium (D) is CK7 weak-irregular positive but (E) CK17 and (F) CEA strongly positive; (G) CK20 and (H) CA125 are negative. (I) p53 shows nuclear positivity in only half of the tumour cells.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.